HOOKIPA Pharma Inc.

HOOK

US43906K1007

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 02:08:49 2024-04-25 pm EDT			5-day change	1st Jan Change
0.819 ^USD	-3.65%		+8.30%	+2.27%

Apr. 24	HOOKIPA Pharma Inc. Announces FDA Clearance of Its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers	CI
Apr. 10	HOOKIPA Pharma Inc. Announces European Medicines Agency Grant Prime Designation for the Investigational Product HB-200	CI

Food and Drug Administration Accepts Hookipa’s Investigational New Drug Application for HB-300

July 25, 2022 at 08:00 am EDT

HOOKIPA Pharma Inc. announced that it has received U.S. Food and Drug Administration (FDA) acceptance of its Investigational New Drug (IND) application for HB-300, a novel arenaviral immunotherapy for the treatment of metastatic castration-resistant prostate cancer.

Latest news about HOOKIPA Pharma Inc.

HOOKIPA Pharma Inc. Announces FDA Clearance of Its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers	Apr. 24	CI
HOOKIPA Pharma Inc. Announces European Medicines Agency Grant Prime Designation for the Investigational Product HB-200	Apr. 10	CI
HOOKIPA Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
HOOKIPA Pharma Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 22	CI
North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
RBC Cuts Price Target on HOOKIPA Pharma to $5 From $6 Amid Restructuring Plan, Termination of Roche Partnership on KRAS; Outperform, Speculative Risk Kept	Jan. 30	MT
HOOKIPA Pharma to Cut 30% of Workforce in Restructuring	Jan. 29	MT
HOOKIPA Pharma Inc. Announces the Appointment of Mark Winderlich as Chief Development Officer, Effective April 1, 2024	Jan. 16	CI
Top Premarket Gainers	Dec. 21	MT
HOOKIPA Pharma Inc. announced that it has received $21.2505 million in funding from Gilead Sciences, Inc.	Dec. 19	CI
HOOKIPA Pharma Inc. Announces Appointment of Dr. Roman Necina as Chief Operations Officer, Effective January 1, 2024	Dec. 01	CI
HOOKIPA Pharma's HIV Vaccine Candidate HB-500 Receives FDA Clearance for Investigational New-Drug Application	Nov. 20	MT
Hookipa Pharma Announces FDA Clearance of Its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus	Nov. 20	CI
HOOKIPA Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
HOOKIPA Pharma Inc. Presents Positive Biomarker and Translational Data on HB-200 Monotherapy At Society for Immunotherapy of Cancer 2023	Nov. 03	CI
HOOKIPA Pharma Says Head, Neck Cancer Phase 2 Study of Therapy Combination Showed 42% Objective Response Rate	23-10-23	MT
Hookipa Pharma Inc. Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023	23-10-22	CI
HOOKIPA Pharma Operations Chief Christine Baker Resigns	23-10-20	MT
HOOKIPA Pharma Inc. Announces Resignation of Christine Baker as Chief Operating Officer, Leaving on January 15, 2024	23-10-20	CI
HOOKIPA Pharma Inc. Announces Publication of Preclinical Data of Hepatitis B Virus Therapeutic Vaccine Developed in Collaboration with Gilead Sciences	23-10-18	CI
HOOKIPA Pharma Inc. Announces Management Changes	23-09-13	CI
Transcript : HOOKIPA Pharma Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-11-2023 03:35 PM	23-09-11
HC Wainwright Adjusts HOOKIPA Pharma Price Target to $6.50 From $8, Maintains Buy Rating	23-08-11	MT
HOOKIPA Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI

Chart HOOKIPA Pharma Inc.

Duration

Period

More charts

Company Profile

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Companyâs replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.

Sector

Pharmaceuticals

Calendar

08:00am - HOOKIPA HB-200 Phase 2 Trial Results Call

More about the company

Income Statement Evolution

More financial data

Ratings for HOOKIPA Pharma Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.85 USD

Average target price

4.89 USD

Spread / Average Target

+475.29%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HOOKIPA PHARMA INC.	+2.27%	84.11M
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.03%	358B
MERCK & CO., INC.	+20.35%	322B
ABBVIE INC.	+8.20%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-11.32%	149B
AMGEN INC.	-6.17%	146B

Other Pharmaceuticals

HOOKIPA Pharma Inc.

Equities

HOOK

US43906K1007

Pharmaceuticals

Food and Drug Administration Accepts Hookipa’s Investigational New Drug Application for HB-300

EPS Revisions